Brought to you by 
Schering-Plough gets second antibody from partner Centocor
18 Aug 2006
Executive Summary
Schering-Plough has exercised its option to license rights to Centocor's human antibody CNTO148 (golimumab). The molecule has completed Phase II testing for rheumatoid arthritis (RA) and will move into Phase III early next year; it is also being developed against other immune-mediated inflammatory diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schering-Plough gets second antibody from partner Centocor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice